







PRIMARY CARE DECISION POINTS IN COPD: **INDIVIDUALIZING TREATMENT**







Vaccinate

Pneumonia, Influenza, SARS-CoV-2, Pertussis (DPT)



Encourage Healthy Lifestyle

Regular Exercise, Healthy Diet, Adequate Sleep, Achieve & Maintain Optimal Weight

> **Assess Oxygen Saturation** Prescribe Supplemental Oxygen if Hypoxic Assess & Treat Co-Morbidities

> > Assess for Other Interventions

Pulmonary Rehabilitation

Consider Pulmonary Consultation



Prevent Progression and Exacerbations

Air Pollution

- Exacerbation Recognition & Management
- Disease Collaborative Self-Management
- Inhalers & Medications

Provide COPD Action Plan


- COPD Foundation
- COPD Foundation App

- American Lung Association

ASSESS SYMPTOMS



Modified Medical Research Council (mMRC) Dyspnea Scale ≥ 2 or COPD Assessment Test (CAT) ≥ 10?



Excercise or

Oxygenation? **Improved**

- **Continue Current** Management
- Check Inhaler Adherence & Technique


Continued or Increased Symptoms

- Check Oxygenation Need, Adherence & Dose
- Pulmonary Rehabilitation Reassessment

Consider Triple Therapy LABA/LAMA/ICS

Consider Pulmonary Consultation

EXACERBATION HISTORY









400









PRIMARY CARE DECISION POINTS INDIVIDUALIZING TREATMENT

COPD DIAGNOSIS



Assess Current Environmental & Occupational





Vaccinate

Pneumonia, Influenza, SARS-CoV-2, Pertussis (DPT)



Encourage Healthy Lifestyle

• Regular Exercise, Healthy Diet, Adequate Sleep, **Achieve & Maintain Optimal Weight**



Education

- Prevent Progression and Exacerbations
- Exacerbation Recognition & Management
- Disease Collaborative Self-Management
- Inhalers & Medications



- American Lung Association
- COPD Foundation
- COPD Foundation App



Assess & Treat Co-Morbidities

Assess for Other Interventions

Pulmonary Rehabilitation

Consider Pulmonary Consultation
















PRIMARY CARE
DECISION POINTS
IN COPD:
INDIVIDUALIZING TREATMENT

ASSESS SYMPTOMS












PRIMARY CARE
DECISION POINTS
IN COPD:
INDIVIDUALIZING TREATMENT

EXACERBATION HISTORY



This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.





